Human immunodeficiency virus transgenic rats exhibit pulmonary hypertension.

Human immunodeficiency virus (HIV)-associated pulmonary arterial hypertension (PAH) is a serious noninfectious disease involving an aberrant increase in pressure in the blood vessels of the lung, which leads to right ventricular (RV) heart failure and can eventually result in death. A lack of viable animal models of HIV-PAH has limited the identification of signaling pathways involved in HIV-mediated onset and progression of PAH. To determine whether the HIV-1 transgenic (HIV Tg) rat displays pathophysiological end points associated with PAH, we evaluated peak RV systolic pressure (RVSP), RV hypertrophy, pulmonary vessel remodeling, and alterations in gene expression by real-time PCR and microarray. RVSP was measured by RV catheterization via the right jugular vein in 3- and 9-mo-old HIV Tg and age-matched Fischer 344 (control) male rats while under 2% isoflurane anesthesia. RVSP was elevated in the HIV Tg rats (34.2 ± 2.5 mmHg) compared with the F344 controls (21.2 ± 2.5 mmHg), with more significant elevations in the 9-mo-old HIV Tg rats (42.5 ± 3.7 mmHg). We observed significant increases in RV wall thickness in HIV Tg rats compared with controls, both histologically and by echocardiograph measurement. HIV Tg rats also show increased thickening of the pulmonary artery and remodeling of small pulmonary arteries, as well as altered expression of gene pathways associated with PAH. These data represent the first analysis of PAH in HIV Tg rats and suggest that this model will be useful for investigating pathways and identifying potential therapies for HIV-PAH.

[1]  J. Lundgren,et al.  Cardiovascular implications from untreated human immunodeficiency virus infection. , 2011, European heart journal.

[2]  M. Oka,et al.  Rho kinase-mediated vasoconstriction in pulmonary hypertension. , 2010, Advances in experimental medicine and biology.

[3]  M. Humbert,et al.  HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era , 2010, AIDS.

[4]  G. Filippatos,et al.  Guidelines for the diagnosis and treatment of pulmonary hypertension , 2009 .

[5]  P. Chrobak,et al.  Adult AIDS-Like Disease in a Novel Inducible Human Immunodeficiency Virus Type 1 Nef Transgenic Mouse Model: CD4+ T-Cell Activation Is Nef Dependent and Can Occur in the Absence of Lymphophenia , 2009, Journal of Virology.

[6]  A. Malik,et al.  Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. , 2009, The Journal of clinical investigation.

[7]  Horst Olschewski,et al.  Updated clinical classification of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.

[8]  J. Seagrave,et al.  Vehicular Emissions Induce Vascular MMP-9 Expression and Activity Associated With Endothelin-1–Mediated Pathways , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[9]  Yue Tian,et al.  Mechanisms responsible for pulmonary hypertension. , 2008, Chinese medical journal.

[10]  C. Lang,et al.  Skeletal and cardiac myopathy in HIV-1 transgenic rats. , 2008, American journal of physiology. Endocrinology and metabolism.

[11]  M. Opravil,et al.  Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era , 2008, AIDS.

[12]  M. Humbert,et al.  Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. , 2008, American journal of respiratory and critical care medicine.

[13]  W. Grossman,et al.  Circulating endothelial microparticle levels predict hemodynamic severity of pulmonary hypertension. , 2008, American journal of respiratory and critical care medicine.

[14]  Jeffrey N. Martin,et al.  Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension , 2008, AIDS.

[15]  S. El-Dahr,et al.  Mechanisms of Disease: the tissue kallikrein–kinin system in hypertension and vascular remodeling , 2007, Nature Clinical Practice Nephrology.

[16]  N. Petrosillo,et al.  Pulmonary hypertension in individuals with HIV infection. , 2006, AIDS.

[17]  M. Frid,et al.  Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. , 2006, Circulation research.

[18]  P. Luciw,et al.  HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques. , 2006, American journal of respiratory and critical care medicine.

[19]  B. Fanburg,et al.  Hypoxia and hypoxia-inducible factor-1alpha promote growth factor-induced proliferation of human vascular smooth muscle cells. , 2006, American journal of physiology. Heart and circulatory physiology.

[20]  M. Hamon,et al.  Transgenic Mice Overexpressing the 5-Hydroxytryptamine Transporter Gene in Smooth Muscle Develop Pulmonary Hypertension , 2006, Circulation research.

[21]  V. Shepherd,et al.  HIV‐1 TAT represses transcription of the bone morphogenic protein receptor‐2 in U937 monocytic cells , 2006, Journal of leukocyte biology.

[22]  J. Lillehaug,et al.  Structural and functional specificities of PDGF‐C and PDGF‐D, the novel members of the platelet‐derived growth factors family , 2005, The FEBS journal.

[23]  W. Seeger,et al.  Reversal of experimental pulmonary hypertension by PDGF inhibition. , 2005, The Journal of clinical investigation.

[24]  P. Grammas,et al.  Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. , 2005, Biochemical and biophysical research communications.

[25]  D. Stewart,et al.  Rescue of Monocrotaline-Induced Pulmonary Arterial Hypertension Using Bone Marrow–Derived Endothelial-Like Progenitor Cells: Efficacy of Combined Cell and eNOS Gene Therapy in Established Disease , 2005, Circulation research.

[26]  L. Rubin,et al.  Introduction: New Insights Into a Challenging Disease A Review of the Third World Symposium on Pulmonary Arterial Hypertension , 2004 .

[27]  M. Humbert,et al.  Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. , 2003, American journal of respiratory and critical care medicine.

[28]  J. Dyck,et al.  In Vivo Gene Transfer of the O2-Sensitive Potassium Channel Kv1.5 Reduces Pulmonary Hypertension and Restores Hypoxic Pulmonary Vasoconstriction in Chronically Hypoxic Rats , 2003, Circulation.

[29]  Jacques I. Benisty.  Cardiology patient page. Pulmonary hypertension. , 2002, Circulation.

[30]  N. Morrell,et al.  Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. , 2002, Progress in cardiovascular diseases.

[31]  J. Dyck,et al.  Dichloroacetate, a Metabolic Modulator, Prevents and Reverses Chronic Hypoxic Pulmonary Hypertension in Rats: Role of Increased Expression and Activity of Voltage-Gated Potassium Channels , 2002, Circulation.

[32]  N. Petrosillo,et al.  Pathogenesis of HIV‐Related Pulmonary Hypertension , 2001, Annals of the New York Academy of Sciences.

[33]  T. Jeffery,et al.  Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. , 2001, Pharmacology & therapeutics.

[34]  R. Trembath,et al.  Altered Growth Responses of Pulmonary Artery Smooth Muscle Cells From Patients With Primary Pulmonary Hypertension to Transforming Growth Factor-&bgr;1 and Bone Morphogenetic Proteins , 2001, Circulation.

[35]  John Arul Phillips,et al.  Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. , 2001, The New England journal of medicine.

[36]  M. Reitz,et al.  An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[37]  G. Semenza,et al.  Partial HIF-1alpha deficiency impairs pulmonary arterial myocyte electrophysiological responses to hypoxia. , 2001, American journal of physiology. Lung cellular and molecular physiology.

[38]  K. Hirata,et al.  Reduced Hypoxic Pulmonary Vascular Remodeling by Nitric Oxide From the Endothelium , 2001, Hypertension.

[39]  M. Yacoub,et al.  Expression of pulmonary vascular angiotensin‐converting enzyme in primary and secondary plexiform pulmonary hypertension , 2000, The Journal of pathology.

[40]  I. Khan,et al.  HIV-Related pulmonary hypertension: analytic review of 131 cases. , 2000, Chest.

[41]  M. Humbert,et al.  Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family , 2000, Journal of medical genetics.

[42]  P. Werahera,et al.  Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. , 1999, The American journal of pathology.

[43]  T. Beaty,et al.  Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha. , 1999, The Journal of clinical investigation.

[44]  L. Chicoine,et al.  Maintained upregulation of pulmonary eNOS gene and protein expression during recovery from chronic hypoxia. , 1999, American journal of physiology. Heart and circulatory physiology.

[45]  C. Heldin,et al.  Mechanism of action and in vivo role of platelet-derived growth factor. , 1999, Physiological reviews.

[46]  S. Eddahibi,et al.  Heart and lung VEGF mRNA expression in rats with monocrotaline- or hypoxia-induced pulmonary hypertension. , 1998, The American journal of physiology.

[47]  S. Kourembanas,et al.  Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension. , 1998, American journal of respiratory cell and molecular biology.

[48]  S. Archer,et al.  Molecular identification of the role of voltage-gated K+ channels, Kv1.5 and Kv2.1, in hypoxic pulmonary vasoconstriction and control of resting membrane potential in rat pulmonary artery myocytes. , 1998, The Journal of clinical investigation.

[49]  M. Juhaszova,et al.  Attenuated K+ channel gene transcription in primary pulmonary hypertension , 1998, The Lancet.

[50]  N. Voelkel,et al.  Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. , 1997, Human pathology.

[51]  R. Speich,et al.  HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. , 1997, American journal of respiratory and critical care medicine.

[52]  P. Kimmel,et al.  Captopril and renal survival in patients with human immunodeficiency virus nephropathy. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[53]  N. Voelkel,et al.  Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. , 1995, The European respiratory journal.

[54]  N. Voelkel,et al.  Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. , 1995, The Journal of clinical investigation.

[55]  S. Jancar,et al.  Studies on the mechanism of PAF-induced vasopermeability in rat lungs. , 1995, Prostaglandins, leukotrienes, and essential fatty acids.

[56]  L. Rubin,et al.  Pathology and pathophysiology of primary pulmonary hypertension. , 1995, The American journal of cardiology.

[57]  J. Coligan,et al.  Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. , 1993, Journal of immunology.

[58]  H. Palevsky,et al.  Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. , 1992, The American review of respiratory disease.

[59]  R. Speich,et al.  Primary pulmonary hypertension in HIV infection. , 1991, Chest.

[60]  B. Brundage,et al.  Pulmonary hypertension: a cellular basis for understanding the pathophysiology and treatment. , 1989, Journal of the American College of Cardiology.

[61]  H. Olschewski,et al.  [Pulmonary hypertension]. , 2012, Deutsche medizinische Wochenschrift.

[62]  G. Simonneau,et al.  Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. , 2008, American journal of respiratory and critical care medicine.